Status: Recruiting
A Study of VET3-TGI in Patients With Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).
Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: KaliVir ImmunotherapeuticsUpdated: Apr 7, 2026Locations: 7
Eligibility criteria
Have pathologically confirmed, advanced, unresectable, or metastatic solid tumor... [+6]
Prior systemic therapy washout (dependent upon the therapy) [+5]